LYEL — Lyell Immunopharma Share News
0.000.00%
Last trade - 00:00- $230.10m
- $26.00m
- $0.04m
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma
Lyell Immunopharma Q1 revenue misses, adjusted net loss narrows
Brief: Lyell Immunopharma Q1 Net Income USD -24.153 Million
Lyell Immunopharma misses Q4 revenue estimates
Brief: Lyell Immunopharma Announces Initiation Of Patient Dosing In First-Of-Its-Kind Phase 3 Car T-Cell Clinical Trial
NASDAQ RESUMED AT 12:14 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:04 PM
U.S. STOCKS ON THE MOVE-Silver miners, Targa Resources, Designer Brands
U.S. STOCKS ON THE MOVE-Clearwater Analytics, Silver miners, Exxon
H.C. Wainwright upgrades Lyell to 'buy' on cell therapy progression
Lyell Immunopharma Q3 adjusted net loss beats estimates
Brief: Charles Newton Resigns As CFO Of Lyell Immunopharma - SEC Filing
Brief: Lyell Immunopharma Announces The Initiation Of A Phase 3 Head-To-Head Car T-Cell Therapy Clinical Trial In Aggressive Large B-Cell Lymphoma And Formation Of Expert Steering Committee
Lyell Immunopharma Inc reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma Inc expected to post a loss of $3.58 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Natgas companies, Eli Lilly, Kraft Heinz